Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twelve ratings firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $54.64.
ANAB has been the topic of a number of recent research reports. Guggenheim boosted their price objective on AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Wedbush reissued an “outperform” rating and set a $42.00 price target on shares of AnaptysBio in a research report on Thursday, September 26th. HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of AnaptysBio in a research report on Wednesday, August 14th. JPMorgan Chase & Co. boosted their target price on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Finally, Truist Financial raised their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th.
Read Our Latest Report on AnaptysBio
Insiders Place Their Bets
Institutional Trading of AnaptysBio
Several hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC acquired a new stake in AnaptysBio in the 1st quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in AnaptysBio in the first quarter valued at approximately $265,000. Susquehanna Fundamental Investments LLC purchased a new position in AnaptysBio in the first quarter worth approximately $1,221,000. Acadian Asset Management LLC purchased a new position in AnaptysBio in the first quarter worth approximately $420,000. Finally, Platinum Investment Management Ltd. acquired a new position in AnaptysBio during the 1st quarter worth approximately $1,490,000.
AnaptysBio Trading Down 0.6 %
NASDAQ:ANAB opened at $32.03 on Wednesday. The company has a market cap of $875.03 million, a P/E ratio of -5.22 and a beta of -0.29. AnaptysBio has a twelve month low of $13.36 and a twelve month high of $41.31. The company’s 50-day moving average price is $35.45 and its 200-day moving average price is $29.72.
AnaptysBio (NASDAQ:ANAB – Get Free Report) last released its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The business had revenue of $10.97 million during the quarter, compared to analysts’ expectations of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. On average, analysts expect that AnaptysBio will post -6.84 earnings per share for the current year.
About AnaptysBio
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
Featured Stories
- Five stocks we like better than AnaptysBio
- Which Wall Street Analysts are the Most Accurate?
- Texas Roadhouse Stock Steering for New Highs This Year
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.